The role and efficacy of osimertinib

Osimertinib, trade name Tagrisso, is a targeted drug mainly used to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is a third-generation EGFRtyrosine kinase inhibitor (TKI), which is different from previous generations of EGFR inhibitors, it has significant clinical advantages, especially in the treatment of EGFR mutation-positive patients who are resistant to first- and second-generation EGFR inhibitors.

The mechanism of action of Osimertinib is mainly by selectively inhibiting the tyrosine kinase activity of EGFR and blocking the growth signals of EGFR mutant (including T790M mutation) cancer cells. EGFR is an important cell surface receptor that participates in biological processes such as cell proliferation, migration, and apoptosis. For patients with non-small cell lung cancer carrying EGFR mutations, targeted EGFR inhibition can effectively inhibit tumor progression.

One of the greatest features of osimertinib is its ability to effectively overcome resistance to previous generations of EGFR inhibitors, especially the T790M mutation. The T790M mutation is the most common resistance mutation in the EGFR gene, making patients resistant to conventional EGFR inhibitors. Osimertinib can specifically target this mutation to restore the efficacy of the drug. Therefore, osimertinib is widely used in patients who are T790M mutation-positive and resistant to first- and second-generation EGFR inhibitors.

In clinical trials, osimertinib showed significant efficacy. For example, inAURA3In the study, osimertinib showed a higher overall response rate and prolonged progression-free survival (PFS) in patients with T790M mutation-positive non-small cell lung cancer. The drug can significantly improve patients' survival expectations and is well tolerated. Compared with traditional chemotherapy and early EGFR inhibitors, the side effects of osimertinib are relatively mild. Common adverse reactions include rash, diarrhea, fatigue, etc., and most side effects are mild to moderate.

Osimertinib is not only effective for EGFR T790M mutation-positive non-small cell lung cancer, but is also approved for first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer patients. According to the results of multiple clinical trials around the world, the efficacy and safety of osimertinib in the first-line treatment of EGFR mutation-positive patients are better than traditional chemotherapy and first-generation EGFR TKIs (such as gefitinib, erlotinib). This makes osimertinib an important treatment option for patients with EGFR mutation-positive non-small cell lung cancer.

Osimertinib is taken orally, once daily, and the recommended dose is 80mg. It can be taken alone or in combination with other drugs, and does not need to be taken with food. It is convenient to use and easy for patients to comply with the treatment plan.

In short, osimertinib is a new type of EGFR tyrosine kinase inhibitor that can effectively treat non-small cell lung cancer patients who are resistant to other EGFR targeted drugs, especially in patients with T790M mutation-positive patients. It provides new treatment options for patients with advanced non-small cell lung cancer and improves patients' quality of life and survival.